Your browser doesn't support javascript.
loading
Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques.
Nelson, Ashley N; Shen, Xiaoying; Vekatayogi, Sravani; Zhang, Shiyu; Ozorowski, Gabriel; Dennis, Maria; Sewall, Leigh M; Milligan, Emma; Davis, Dominique; Cross, Kaitlyn A; Chen, Yue; van Schooten, Jelle; Eudailey, Joshua; Isaac, John; Memon, Saad; Weinbaum, Carolyn; Stanfield-Oakley, Sherry; Byrd, Alliyah; Chutkan, Suni; Berendam, Stella; Cronin, Kenneth; Yasmeen, Anila; Alam, S Munir; LaBranche, Celia C; Rogers, Kenneth; Shirreff, Lisa; Cupo, Albert; Derking, Ronald; Villinger, Francois; Klasse, Per Johan; Ferrari, Guido; Williams, Wilton B; Hudgens, Michael G; Ward, Andrew B; Montefiori, David C; Van Rompay, Koen K A; Wiehe, Kevin; Moore, John P; Sanders, Rogier W; De Paris, Kristina; Permar, Sallie R.
Affiliation
  • Nelson AN; Department of Pediatrics, Weill Cornell Medicine; New York, NY, USA.
  • Shen X; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Vekatayogi S; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Zhang S; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Ozorowski G; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Dennis M; Department of Pediatrics, Weill Cornell Medicine; New York, NY, USA.
  • Sewall LM; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Milligan E; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill; Chapel Hill, NC, USA.
  • Davis D; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill; Chapel Hill, NC, USA.
  • Cross KA; Gillings School of Public Health and Center for AIDS Research, University of North Carolina at Chapel Hill; Chapel Hill, NC, USA.
  • Chen Y; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • van Schooten J; Department of Medical Microbiology, Academic Medical Center; Amsterdam, Netherlands.
  • Eudailey J; Department of Pediatrics, Weill Cornell Medicine; New York, NY, USA.
  • Isaac J; Department of Pediatrics, Weill Cornell Medicine; New York, NY, USA.
  • Memon S; Department of Pediatrics, Weill Cornell Medicine; New York, NY, USA.
  • Weinbaum C; Department of Pediatrics, Weill Cornell Medicine; New York, NY, USA.
  • Stanfield-Oakley S; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Byrd A; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Chutkan S; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Berendam S; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Cronin K; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Yasmeen A; Department of Microbiology and Immunology, Weill Cornell Medicine; New York, NY, USA.
  • Alam SM; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • LaBranche CC; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Rogers K; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
  • Shirreff L; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
  • Cupo A; Department of Microbiology and Immunology, Weill Cornell Medicine; New York, NY, USA.
  • Derking R; Department of Medical Microbiology, Academic Medical Center; Amsterdam, Netherlands.
  • Villinger F; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • Klasse PJ; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
  • Ferrari G; Department of Microbiology and Immunology, Weill Cornell Medicine; New York, NY, USA.
  • Williams WB; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Hudgens MG; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Ward AB; Gillings School of Public Health and Center for AIDS Research, University of North Carolina at Chapel Hill; Chapel Hill, NC, USA.
  • Montefiori DC; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Van Rompay KKA; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Wiehe K; California National Primate Research Center, University of California; Davis, CA, USA.
  • Moore JP; Human Vaccine Institute, Duke University Medical Center; Durham, NC, USA.
  • Sanders RW; Department of Microbiology and Immunology, Weill Cornell Medicine; New York, NY, USA.
  • De Paris K; Department of Medical Microbiology, Academic Medical Center; Amsterdam, Netherlands.
  • Permar SR; Department of Microbiology and Immunology, Weill Cornell Medicine; New York, NY, USA.
bioRxiv ; 2023 Nov 11.
Article in En | MEDLINE | ID: mdl-37986885
ABSTRACT
A vaccine that can achieve protective immunity prior to sexual debut is critical to prevent the estimated 410,000 new HIV infections that occur yearly in adolescents. As children living with HIV can make broadly neutralizing antibody (bnAb) responses in plasma at a faster rate than adults, early childhood is an opportune window for implementation of a multi-dose HIV immunization strategy to elicit protective immunity prior to adolescence. Therefore, the goal of our study was to assess the ability of a B cell lineage-designed HIV envelope SOSIP to induce bnAbs in early life. Infant rhesus macaques (RMs) received either BG505 SOSIP or the germline-targeting BG505 GT1.1 SOSIP (n=5/group) with the 3M-052-SE adjuvant at 0, 6, and 12 weeks of age. All infant RMs were then boosted with the BG505 SOSIP at weeks 26, 52 and 78, mimicking a pediatric immunization schedule of multiple vaccine boosts within the first two years of life. Both immunization strategies induced durable, high magnitude binding antibodies and plasma autologous virus neutralization that primarily targeted the CD4-binding site (CD4bs) or C3/465 epitope. Notably, three BG505 GT1.1-immunized infants exhibited a plasma HIV neutralization signature reflective of VRC01-like CD4bs bnAb precursor development and heterologous virus neutralization. Finally, infant RMs developed precursor bnAb responses at a similar frequency to that of adult RMs receiving a similar immunization strategy. Thus, a multi-dose immunization regimen with bnAb lineage designed SOSIPs is a promising strategy for inducing protective HIV bnAb responses in childhood prior to adolescence when sexual HIV exposure risk begins.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2023 Document type: Article Affiliation country: